Reading OGEN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OGEN free→
ORAGENICS INC (OGEN)
AMEXHealth CareBiotechnologySnapshot 2026-06-16
Watch· this week
$0.61-1.63%
Close 2026-06-16 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is weak, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, and it has a capital-friendly stance. Risk is high, and the sector backdrop is a headwind, with OGEN compared to sector peers being below typical. If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting OGEN and other Healthcare names. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- AMEX
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $2.82M
- Employees
- —
- IPO date
- 2003-11-13
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.61. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfair
$0.65consensus
Range $0.65 – $0.65
vs price: -5% below
Method agreement — · 1 method
No-growth: today's peer multiple on trailing earnings. The headline read.
3-year—
—consensus
Range — – —
vs price: —
Method agreement —
Embeds projected growth. Leans optimistic by design. Upside context.
5-year—
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peersmedium confidence
At $0.62 OGEN trades at 9× p/s, below its 9× p/s peer median. Our $0.65 fair value sits above the price; medium confidence. Not investment advice.
Multiple (P/S)
9.1x
peer 9.4x · own history —
Premium
1.0x peer
Growth the price needs
-3%
our forecast —
Our fair value
$0.65
range $0.65 – $0.65
WhyEarnings too small for P/E
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fair12-month view
What's priced in
The price sits about 3% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Compared to peers
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
weakOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
29th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.01x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
Management & capital allocation
neutral10 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: Mature by revenue growth · theme biologics/biosimilars.headwind-10.0%sector vs S&P 500, 60d
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
AI cycle regime · market-wide
2-axis classifierLong-term · 1–3 yr
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weakProvisional
- Capital allocation
- weak
- Margin discipline
- weak
- Balance sheet
- weak
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$298.
How much price usually moves either way.
On a bad day, this stock has moved -$809.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,847.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
Valuation changed. The valuation label moved from "fair" to "None." Risk remained high. The sector backdrop is a headwind. Earnings quality is loss-making. Recent performance is weak. Management is neutral.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-05-181mo agoInvesting.com India
Advancement in drug trial supports product development goals.
Strongly reinforcesUnconfirmed report
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting OGEN and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for OGEN and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping OGEN and other Healthcare names could fade. Watch these names for early warning.
- If OGEN misses again next quarter like this past one (a very large miss off a near-zero prior-year base on the 2025-09-30 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits OGEN and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-03-113mo agoItem 8.01
OTHER INFORMATION. On March 10, 2026, Oragenics, Inc. (the “Company”) issued a press release announcing that it had received final Human Research Ethics Committee (HREC) approval in Australia to commence the Company’s Phase IIa clinical trial evaluating the Company’s lead drug candidate, ONP-002, for the treatment of concussion and mild traumatic brain injury (mTBI). On March 11, 2026, the Company issued a press release announcing that the Company is exploring discussions with third parties r…
M&A activitypositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-22 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.